LEQEMBI® update from Eisai's investor presentation of their quarterly

 BioArctic AB's (publ) (NASDAQ; BIOA B) (Stockholm: BIOA B) partner Eisai today held a presentation on the second quarter of Eisai's fiscal year, ending March 2024. In addition to presenting sales numbers of 0.4 billion yen for LEQEMBI for the period, Eisai also stated the following;

• The launch of LEQEMBI in the U.S. is progressing as planned and the company reiterated their expectation that 10,000 patients will be on LEQEMBI by the end of March 2024
• The number of neurologists or other Alzheimer disease (AD) specialists who are ready to diagnose, treat and monitor patients on LEQEMBI has increased from approximately 1,400 in June to 2,500 in October
• 60% of the top 100 Integrated Delivery Networks (IDN^[1]) in the U.S. have now approved LEQEMBI, which means the treatment is available within their health system
• Eisai aims to achieve 10 billion yen (M 700 SEK in today's currency) level revenue from LEQEMBI in their fiscal year 2023, ending March 2024 (not to be seen as guidance). BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region.

BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.

https://www.biospace.com/article/releases/update-relating-to-leqembi-from-eisai-s-investor-presentation-of-their-quarterly-report-published-today/